
Bloody Minded Episode 106 - Seal Team L | Chronic Lymphocytic Leukaemia (CLL)
Sep 29, 2026
A lively tour through chronic lymphocytic leukaemia, from mysterious smudge cells and flow cytometry to IGHV status, staging and modern targeted treatments. The discussion covers monoclonal B-cell lymphocytosis, small lymphocytic lymphoma, infection risks, watchful waiting, venetoclax and BTK inhibitors, before tackling complications and Richter transformation, with a few seal-themed detours along the way.
AI Snips
Chapters
Transcript
Episode notes
Why Mutated IGHV Predicts Better Outcomes
- IGHV mutation status reflects the CLL cell’s developmental origin and predicts disease behavior.
- Mutated IGHV usually means slower expansion, whereas unmutated IGHV signals stronger B-cell receptor signaling and more aggressive disease.
CLL Survives Through BTK And BCL2
- Autonomous B-cell receptor signaling sustains CLL growth through BTK, while BCL2 overexpression prevents apoptosis.
- These mechanisms explain why BTK and BCL2 inhibitors became central targeted treatments.
MBL And SLL Clarify CLL Progression
- MBL is a common, usually asymptomatic precursor with fewer than 5 × 10⁹ clonal B cells per litre.
- CLL and SLL are biologically identical; their names mainly reflect blood versus nodal distribution.
